Product information 

Ready to use, synthetic and free of any animal-origin component 


rAAV (Adeno-Associated Virus) manufacturing using HEK-293 derivative cells 

Number of transfections 

1 L of FectoVIR®-AAV transfection reagent is sufficient to transfect on average 500 L of cell culture (using standard conditions) 

Storage condition 

Store FectoVIR®-AAV at 5 °C ± 3°C. 
Expiry date is indicated in the certificate of analysis and on the product. 

Product documentation 

Certificate of Analysis 
Certificate of origin 
Non-hazardous product statement 

Regulatory documentation (FectoVIR®-AAV GMP only) 

Certificate of compliance 
Drug master file
Protocols for identity and activity testing 
Regulatory support package including toxicity statement
Quality agreement 


FectoVIR®-AAV is a novel generation of synthetic transfection reagent specifically developed for industrial scale production of recombinant AAV (rAAV) in both suspension and adherent HEK-293 derivative cell systems. FectoVIR®-AAV transfection reagent guarantees higher rAAV titers, improves scalability for large scale production and de-risks manufacturing process with it’s availability at pharma GMP grade. FectoVIR®-AAV-GMP is manufactured under a validated and aseptic process in compliance with ICH Q7, GMP part II guidelines, the quality grade of reference for active pharmaceutical ingredients (API).

Ordering Information

Reference NumberProduct  Amount of reagent
101000044FectoVIR®-AAVFectoVIR®-AAV 1 mL
101000022FectoVIR®-AAVFectoVIR®-AAV 10 mL
101000004FectoVIR®-AAVFectoVIR®-AAV 100 mL
101000054FectoVIR®-AAVFectoVIR®-AAV 1 L
102000006FectoVIR®-AAV GMPFectoVIR®-AAV GMP 100 mL Bottle
102000009FectoVIR®-AAV GMPFectoVIR®-AAV GMP 1 L Bag
120-001***NODISPLAY*** ***NO DISPLAY*** 1 ml***NODISPLAY***
120-010***NODISPLAY******NO DISPLAY*** 10 ml***NODISPLAY***
120-100***NODISPLAY******NO DISPLAY*** 100 ml***NODISPLAY***

Larger pack sizes available upon request. Please contact us .


Want to request a quote

Get Now


Superior AAV yields to increase the number of doses per production batch

Titer value is the critical measurement to evaluate cost reduction. The choice of the transfection reagent has a direct impact on manufacturing costs. In comparison to gold standard PEIpro® and other competitor transfection reagents, FectoVIR®-AAV stands out with its unmatched performance in producing highest rAAV yields in suspension cell culture systems. FectoVIR®-AAV reproducibly improves AAV production yield with up to a remarkable 10-fold increase in viral genome titer compared to other competitors. 

Achieving process economics by process intensification to decrease manufacturing costs 

The transfection reagent is a key raw material that can provide direct cost benefits. With its remarkable performance, FectoVIR®-AAV enables process intensification by increasing productivity. By producing more rAAV particles, a greater number of doses is achieved for a same batch volume, meaning a reduction in the cost per dose (less labor and raw materials) and a reduction in footprint (fewer or smaller bioreactors for lower capital expenses) to bring the total manufacturing cost down. 

Industrial scalability with low complexation volume

Scalability is essential to guarantee the development of high-yielding and reliable rAAV viral vector manufacturing process for commercialization. Large scale transient transfection implies that large volumes of transfection complexes need to be prepared and added to suspension cells within a given time frame for the transfection to be efficient. FectoVIR®-AAV solves volume constraint. FectoVIR®-AAV has been optimized to reduce the complexation volume down to 1%, facilitating the preparation of transfection complexes for large scale manufacturing. For example, for a 2000 L cell suspension volume, the transfection complexation volume can be optimized down from 200 L (10%) to 20 L (1%).

Industrial scalability with longer complex stability

Large scale transient transfection requires addition of a larger volume of transfection complexes to suspension cell culture, which means longer transfer time. With FectoVIR®-AAV, the transfer time is no longer a limiting factor that can lead to viral titer yield variability. FectoVIR®-AAV transfection complexes show tremendous stability: upon mixing FectoVIR®-AAV transfection reagent and plasmid DNA, transfection complexes can be reliably added to cells within 3h with no significant variation in rAAV titer yields.

Ensuring patient safety: cGMP grade transfection reagent to derisk AAV manufacturing

FectoVIR®-AAV GMP is produced in a two-step process in compliance with ICH Q7 GMP Part II (Eudralex Vol 4, Part II) ensuring validated and aseptic manufacturing process to maximize the transfection reagent quality. FectoVIR®-AAV 1 L bag allows to work in closed system with MPC connection and weldable c-flex tubing to decrease contamination risks. Polyplus accompanies each customer with complementary regulatory support regulatory filings (IND and BLA) in addition of a full set of documentation to ensure traceability and quality of the product. A residual test, to analyze the transfection reagent present/absence in the drug product, is available through selected service providers.

Zoom on the importance of quality for viral vector manufacturing optimization

AAV Gene therapy manufacturers must meet regulatory requirements across their manufacturing process to ensure patient safety. Transfection reagents are ancillary materials, which are used during the manufacturing but are not intended to be present in the final drug product. Benefit from Polyplus’ regulatory expertise to 

  • Understand current CGMP practices for raw materials 
  • Improve risk mitigation 
  • Rely on QbD to enhance quality of manufacturing process 

Looking for a Product Protocol or Certificate of Analysis

Create an Account

Other sources to help you understand FectoVIR®-AAV better

Other Sources

Check our FAQs

These FAQs are organized by application to guide you to find the best answer possible.

Product Documents

You have access to all the documents related to the transfection reagent.

Polyplus Database

Search for publications in our Transfection Database with Polyplus transfection reagents


This lexicon will help you to understand the different terms related to Polyplus-transfection®.

Learn more



Optimizing Plasmid Ratios to Enhance rAAV Production
Improving the Productivity and Packaging Efficiency of AAV Manufacturing Processes via a Process Intensification DoE Approach
Easy – rAAV pTransgene Plasmid


Webinar Replay : Optimization-by-Design – A critical factor in successful viral vector scale up
Webinar Replay : Straightforward AAV manufacturing process scale up from bench-scale to 2000L STR
Webinar replay: Next Generation of Genetic Engineered AAV Helper Plasmids


Poster : Enhancing AAV productivity through Helper plasmid design and plasmid ratio optimization
Infographic : Polyplus solutions for viral vector production
Infographic : GMP AAV manufacturing process using transient transfection in a 2 000 L bioreactor (Theoretical approach)

View All Resources